MedTrace Logo

Influence of Body Composition on Chemotherapy Outcomes in Localized Breast Cancer

NCT05858398 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2026-01-02

No results posted yet for this study

Summary

The purpose of this study is to determine if pharmacokinetics of docetaxel is modified by the body composition (assessed by the BMI but also by CT-scan) in patients treated by docetaxel as adjuvant treatment of a localized breast cancer

Conditions

Interventions

BIOLOGICAL

pharmacokinetics blood sample assessment

pharmacokinetics blood sample assessment during the first exposure to docetaxel

Sponsors & Collaborators

  • Erasmus Medical Center

    collaborator OTHER

  • Universitaire Ziekenhuizen KU Leuven

    collaborator OTHER

  • Centre Henri Becquerel

    lead OTHER

Principal Investigators

  • Florian Clatot, Prof · Centre Henri Becquerel

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-10-25
Primary Completion
2026-05-02
Completion
2027-05-02

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05858398 on ClinicalTrials.gov